查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984130

大腸直腸癌篩檢和診斷市場：按類型、產品類型、應用和最終用戶分類－2026-2032年全球市場預測

Colorectal Cancer Screening & Diagnostic Market by Type, Product, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，大腸癌篩檢和診斷市場價值將達到 8.3026 億美元，到 2026 年將成長至 9.0461 億美元，到 2032 年將達到 14.9245 億美元，複合年成長率為 8.73%。

主要市場統計數據
基準年 2025 8.3026億美元
預計年份：2026年 9.0461億美元
預測年份 2032 1,492,450,000 美元
複合年成長率 (%) 8.73%

對改變大腸直腸癌篩檢和診斷的臨床、經濟和營運趨勢進行了簡潔而全面的概述。

大腸直腸癌仍然是癌症發病率和死亡率的主要原因之一，隨著臨床醫生、保險公司和患者對更便利、更準確、更經濟有效的篩檢和診斷方法的需求日益成長，篩檢和診斷格局正在迅速變化。過去十年，非侵入性檢測、影像學和分子診斷技術的進步使臨床路徑更加多樣化，而公共衛生措施也加大了提高高風險族群篩檢率的力度。因此，目前的生態系統涵蓋了傳統胃腸病學家以外的更廣泛的相關人員，包括基層醫療提供者、診斷實驗室、門診手術中心以及專注於數位醫療和遠端病人參與的供應商。

從整體觀點患者偏好、技術進步、保險公司的壓力以及跨部門合作如何重新定義篩檢途徑和實施動態。

近年來，多項協同變化正在重塑大腸直腸癌篩檢和診斷的實踐。首先，病人的偏好以及醫療系統接受這些偏好的能力，加速了人們對非侵入性居家篩檢方法的興趣，這些方法減少了對醫療機構檢查的依賴。同時，糞便檢驗和血液分子檢測技術的進步也促進了這一轉變，旨在平衡可及性和診斷性能。其次，影像和內視鏡平台在功能和舒適度方面不斷改進。雖然大腸鏡檢查仍然是診斷的黃金標準，但CT結腸成像和高解析度內視鏡檢查擴大用於風險分層和作為替代診斷方案。

到 2025 年，美國關稅政策的變化將如何影響診斷領域的採購、供應鏈韌性和臨床部署途徑？

新的關稅措施和貿易政策的轉變對結直腸癌篩檢和診斷領域的相關人員有重大影響。進口關稅的變化可能會增加CT掃描儀、內視鏡等設備以及試劑盒、試劑等耗材的到岸成本，從而影響醫院、門診手術中心和診斷檢查室的採購時間和資本投資決策。為此，醫療機構和經銷商可能會推遲非緊急採購，優先採購可更換的耗材，或與供應商重新談判合約以維持營運預算。

全面的細分分析揭示了類型、產品類型、應用和最終用戶趨勢如何決定採用、採購和臨床效用。

從檢測類型角度分析市場，可以發現篩檢檢測和糞便檢驗之間存在著微妙的共生關係。篩檢檢測包括血液檢測和影像檢查，而影像檢查又包括大腸鏡檢查、CT結腸影像和乙狀結腸鏡檢查。在這種結構中，大腸鏡檢查仍然是確診和治療性介入的首選方法，而CT結腸成像則是一種侵入性較小的影像學檢查方式，尤其對那些不願接受傳統大腸鏡檢查的患者俱有吸引力。乙狀結腸鏡檢查在群體篩檢中的重要性正在下降，但在某些臨床情況和監測通訊協定中仍然有用。血液檢測是一種新的風險分層輔助工具，當與檢驗的預後標記結合使用時，可能會影響轉診模式。

區域分析詳細說明了基礎設施、政策和文化因素如何導致世界各地市場出現不同的採用模式和策略重點。

區域趨勢對篩檢和診斷策略的實施方式有顯著影響。在美洲，完善的篩檢項目、健全的檢測基礎設施以及鼓勵預防保健的健康環境，促進了糞便檢驗和大腸鏡檢查的廣泛應用；同時，私營部門的創新也在加速更先進的分子檢測技術的普及。而歐洲、中東和非洲地區的情況較為複雜，既有的公共衛生篩檢措施與資源分配不均並存。西方市場強調以指南為基礎的篩檢路徑和集中式檢測網路，而中東和非洲部分地區則面臨檢測能力不足的問題，因此更傾向於採用非侵入性、對基礎設施要求較低的方法來擴大檢測覆蓋範圍。

策略性企業展望，闡述創新、夥伴關係與證據生成如何塑造競爭定位和長期差異。

在整體競爭格局中，成熟的醫療設備和診斷公司正採取互補策略，將產品創新與合作夥伴關係建構結合。有些公司專注於改進儀器平台和內視鏡的人體工學設計，以提升臨床療效和手術效率；而其他公司則優先開發先進試劑和高靈敏度耗材，例如糞便DNA檢測，以擴大非侵入性篩檢的覆蓋範圍。此外，一些專業實驗室和診斷Start-Ups正在推動新的分子和血液學方法的發展，旨在將其整合到現有的臨床工作流程中，並提供擴充性的檢測解決方案。

採取切實可行的策略行動，加快製造商、醫療保健提供者和保險公司的採用速度，降低業務風險，並使創新與保險公司和臨床優先事項保持一致。

產業領導者應優先考慮組合式策略，在投資高影響力設備的同時，兼顧擴充性的耗材解決方案，以實現廣泛應用。強調模組化產品架構和靈活的服務契約，有助於製造商減少醫院和門診手術中心的採購摩擦，並幫助診斷檢查室簡化檢測流程。同時，產生以患者療效、成本效益和實際效用為重點的臨床證據，有助於加強與支付方的談判，並促進相關技術被納入臨床指南。儘早與健保機構和醫療技術評估機構建立持續對話，也將加速相關技術獲得保險覆蓋和推廣應用。

本分析採用透明的混合方法研究途徑，說明了生成本分析過程中採用的主要參與、證據三角驗證和品質保證流程。

本分析整合了結構化混合方法的研究證據，結合了與臨床專家、實驗室管理人員和採購人員的初步定性訪談，以及對同行評審的臨床文獻和公開監管文件的系統性回顧。初步研究包括對醫院、門診手術中心、診斷檢查室和研究機構進行詳細訪談，以了解其營運限制、採購行為和臨床偏好。次要資訊用於將臨床指南、技術進步和法規環境置於特定背景下進行解讀，以確保對趨勢的解釋與當前的實踐相符。

對策略重點和循證要求進行簡潔整合，這將影響大腸癌篩檢和診斷的引入和影響。

大腸直腸癌篩檢和診斷領域正朝著以患者為中心、實證醫學為基礎、營運整合的醫療模式轉變。產品和服務，特別是非侵入性檢測方法和耗材，有助於提高醫療服務的可近性並緩解產能瓶頸，而影像和內視鏡平台則繼續提供強大的診斷和治療能力。貿易政策和採購趨勢增加了策略複雜性，凸顯了供應鏈韌性以及在生產和分銷環節採取本地化策略的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：大腸直腸癌篩檢和診斷市場：按類型分類

  • 篩檢測試
    • 驗血
    • 影像檢查
      • 大腸鏡檢查
      • CT結腸成像
      • 乙狀結腸鏡檢查
  • 糞便檢驗
    • 糞便免疫化學檢查
    • 基於癒創木脂法的大便潛血試驗
    • 多標靶糞便DNA檢測

第9章：大腸直腸癌篩檢和診斷市場：按產品分類

  • 消耗品
    • 成套工具
    • 試劑
  • 裝置
    • CT掃描儀
    • 內視鏡

第10章：大腸直腸癌篩檢和診斷市場：按應用領域分類

  • 疾病監測
  • 早期檢測
  • 預後評估

第11章：大腸直腸癌篩檢和診斷市場：按最終用戶分類

  • 門診手術中心
  • 測試機構
  • 醫院
  • 研究機構

第12章：大腸直腸癌篩檢和診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：大腸直腸癌篩檢與診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：大腸直腸癌篩檢和診斷市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國大腸癌篩檢與診斷市場

第16章：中國大腸癌篩檢與診斷市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Clinical Genomics Technologies Pty Ltd.
  • Eiken Chemical Co., Ltd.
  • Epigenomics AG
  • Exact Sciences Corp.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • KARL STORZ SE & Co. KG
  • Medtronic PLC
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Novartis AG
  • Novigenix SA
  • Olympus Corporation
  • Prenetics Global Limited
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Siemens AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AF41

The Colorectal Cancer Screening & Diagnostic Market was valued at USD 830.26 million in 2025 and is projected to grow to USD 904.61 million in 2026, with a CAGR of 8.73%, reaching USD 1,492.45 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 830.26 million
Estimated Year [2026] USD 904.61 million
Forecast Year [2032] USD 1,492.45 million
CAGR (%) 8.73%

A concise but comprehensive overview of the evolving clinical, economic, and operational forces transforming colorectal cancer screening and diagnostics

Colorectal cancer remains a leading cause of cancer morbidity and mortality, and the screening and diagnostic landscape is evolving rapidly as clinicians, payers, and patients seek more accessible, accurate, and cost-effective approaches. Over the past decade, advances in noninvasive testing, imaging modalities, and molecular diagnostics have diversified clinical pathways, while public health initiatives have intensified efforts to increase screening uptake among at-risk populations. As a result, the ecosystem now includes a broader range of stakeholders beyond traditional gastrointestinal specialists, encompassing primary care providers, diagnostics laboratories, ambulatory surgical centers, and technology vendors focused on digital health and remote patient engagement.

Clinical practice guidelines continue to emphasize early detection and risk-appropriate screening, and this has spurred investment in technologies that reduce barriers to participation. Simultaneously, the healthcare delivery context has placed renewed emphasis on patient experience and operational efficiency, prompting providers to adopt stool-based testing and streamlined referral pathways that can reduce the burden on endoscopy suites. Regulatory frameworks and payer policies are adapting to accommodate new evidence, increasing the importance of robust clinical validation and real-world outcomes. Consequently, industry players must navigate a confluence of clinical, economic, and logistical factors to deliver solutions that align with evolving standards of care and stakeholder expectations.

In this environment, a strategic view that integrates the diversity of screening modalities, the segmentation of product types, and the variability of end-user settings is essential for identifying sustainable opportunities. The following sections examine the transformative shifts, regulatory and trade pressures, segmentation dynamics, regional nuances, competitive behavior, and actionable recommendations that together define the contemporary colorectal cancer screening and diagnostics domain.

An integrated view of how patient preferences, technological advances, payer pressures, and cross-sector collaboration are redefining screening pathways and adoption dynamics

The past several years have witnessed multiple converging shifts that are reshaping colorectal cancer screening and diagnostic practice. First, patient preference and system capacity have accelerated interest in noninvasive, home-based screening modalities that reduce dependency on facility-based procedures. This shift is complemented by technological progress in stool-based assays and blood-based molecular tests that aim to balance accessibility with diagnostic performance. Second, imaging and endoscopic platforms continue to improve in capability and comfort, where colonoscopy remains the diagnostic gold standard but CT colonography and enhanced endoscopic imaging are increasingly used for risk stratification and alternative diagnostic algorithms.

Concurrently, payer policies and quality metrics are exerting pressure on screening pathways to deliver measurable population health outcomes, prompting providers to implement organized screening programs and reminder systems. Diagnostics laboratories and instrument manufacturers are responding by enhancing automation, integrating digital reporting, and fostering interoperability with electronic health records to streamline workflows. Additionally, the emergence of precision oncology concepts is driving demand for diagnostics that support early detection, prognosis assessment, and personalized post-diagnostic monitoring. Lastly, cross-sector collaboration among clinical researchers, technology vendors, and health systems has accelerated evidence generation, enabling faster translation of promising assays into routine care. Together, these dynamics create an environment where scalability, demonstrated clinical utility, and operational integration determine which innovations achieve sustained adoption.

How evolving United States tariff policies for 2025 are likely to reverberate across procurement, supply chain resilience, and clinical adoption pathways in diagnostics

Emerging tariff measures and trade policy shifts have meaningful implications for stakeholders operating in the colorectal cancer screening and diagnostics space. Changes in import duties can increase the landed cost of instruments such as CT scanners and endoscopes, as well as consumables including kits and reagents, thereby influencing procurement timing and capital expenditure decisions by hospitals, ambulatory surgical centers, and diagnostics laboratories. In response, healthcare providers and distributors may delay nonurgent purchases, prioritize replaceable consumables, or renegotiate supplier contracts to preserve operating budgets.

Moreover, tariffs can amplify supply chain fragility by incentivizing suppliers to reconfigure production footprints, pursue nearshoring, or source alternative component vendors. This reconfiguration can lead to transitional disruptions in availability and lead times. To mitigate these effects, manufacturers often accelerate localization of assembly or partner with domestic suppliers, a process that can introduce short-term cost increases but ultimately enhance resilience. Clinically, any procurement delays or cost pressures may shift the balance toward lower-resource, minimally invasive screening options that maintain throughput while limiting capital strain.

Finally, tariff-driven cost pressures also interact with reimbursement policies and payer negotiations. Health systems and diagnostics providers will need to demonstrate cost-effectiveness and operational value more rigorously when facing higher acquisition costs. As a result, organizations that proactively model scenarios, diversify supply chains, and engage in strategic sourcing partnerships will be better positioned to preserve access to advanced diagnostics while managing the financial implications of evolving trade policy.

Comprehensive segmentation synthesis revealing how type, product, application, and end-user dynamics determine adoption, procurement, and clinical utility

Analyzing the market through the lens of testing type reveals nuanced coexistence between Screening Tests and Stool Tests, where Screening Tests encompass Blood Tests and Imaging Tests, and Imaging Tests include Colonoscopy, CT Colonography, and Flexible Sigmoidoscopy. Within this structure, Colonoscopy retains primacy for definitive diagnosis and therapeutic intervention, while CT Colonography serves as a less invasive imaging alternative particularly attractive to patients averse to traditional colonoscopy. Flexible Sigmoidoscopy has diminished in prominence for population screening, yet it remains relevant in specific clinical contexts and surveillance protocols. Blood Tests are an emerging adjunct for risk stratification and may influence referral patterns when coupled with validated prognostic markers.

From a product perspective, the distinction between Consumables and Instruments shapes adoption dynamics. Consumables, comprising Kits and Reagents, are central to scaling stool-based and molecular testing programs because they support decentralized specimen collection and laboratory automation. Instruments, notably CT Scanners and Endoscopes, represent longer-term capital investments and require coordinated scheduling, maintenance, and clinician training. Consequently, organizations that offer integrated consumable supply and instrument support tend to secure deeper penetration across clinical settings.

Application segmentation-Disease Monitoring, Early Detection, and Prognosis Assessment-highlights how different technologies align with distinct clinical needs. Early Detection remains the principal driver of population screening initiatives, leveraging fecal immunochemical tests and multitarget stool DNA testing to maximize participation, whereas Disease Monitoring and Prognosis Assessment increasingly rely on molecular assays and, in some cases, blood-based biomarkers to manage post-treatment surveillance and personalize follow-up intervals. The end-user landscape composed of Ambulatory Surgical Centers, Diagnostics Laboratories, Hospitals, and Research Institutes further influences product selection; for example, diagnostics laboratories favor high-throughput kits and reagents, hospitals prioritize integrated instrument ecosystems with strong service agreements, ambulatory surgical centers emphasize throughput and patient flow for endoscopic procedures, and research institutes focus on innovative assays and clinical validation for emerging modalities.

Understanding these intersecting segmentation dimensions clarifies where investment and clinical evidence will yield the greatest impact. Products that bridge consumable convenience with robust analytical performance, supported by service models that reduce operational friction for end users across settings, will be best positioned to influence standard practice and sustain adoption.

Regional analysis detailing how infrastructure, policy, and cultural factors drive differentiated adoption patterns and strategic priorities across global markets

Regional dynamics exert a powerful influence on how screening and diagnostic strategies are implemented. In the Americas, organized screening programs, strong laboratory infrastructure, and payer environments that reward preventive care have supported broad use of stool-based tests and colonoscopy, while private sector innovation has accelerated adoption of higher-complexity molecular assays. Meanwhile, Europe, the Middle East & Africa presents a heterogeneous landscape where established public health screening initiatives coexist with resource variability; western European markets emphasize guideline-driven screening pathways and centralized laboratory networks, whereas parts of the Middle East & Africa face capacity constraints that favor noninvasive, low-infrastructure approaches for expanding access.

Asia-Pacific exhibits a rapid pace of technology adoption and a growing emphasis on population health initiatives, with several countries investing in endoscopy capacity and molecular diagnostics to address rising cancer burdens associated with demographic shifts. In many markets across this region, digital health solutions and mobile outreach are leveraged to increase screening uptake, and local manufacturing partnerships are increasingly common to support regional supply chains. Across all regions, the interplay between regulatory approvals, reimbursement frameworks, and clinician training determines the speed and scale of adoption. Ultimately, stakeholders seeking to expand presence or deploy new technologies must tailor strategies to regional policy priorities, infrastructure readiness, and cultural factors that influence patient participation in screening programs.

Strategic corporate outlook explaining how innovation, partnerships, and evidence generation are shaping competitive positioning and long-term differentiation

Across the competitive landscape, established medical device manufacturers and diagnostics companies are pursuing complementary strategies that blend product innovation with alliance building. Some organizations concentrate on refining instrument platforms and endoscope ergonomics to enhance clinical outcomes and procedure efficiency, while others prioritize the development of high-sensitivity consumables such as advanced reagents and stool DNA assays aimed at broadening noninvasive screening uptake. Additionally, a cohort of specialty laboratories and diagnostic startups is advancing novel molecular assays and blood-based approaches designed to integrate with existing clinical workflows and provide scalable testing solutions.

Partnerships between device manufacturers, laboratory networks, and digital health providers have become a common pathway to accelerate market access and clinical validation. These collaborations enable bundled offerings that include test kits, laboratory processing, reporting platforms, and patient outreach tools, thereby addressing key barriers to screening adherence. Mergers and acquisitions remain a strategic lever for companies seeking to secure complementary capabilities, expand geographic reach, or internalize critical supply components. Furthermore, regulatory milestones and the generation of real-world evidence are decisive in differentiating competitive positioning, as payers and providers increasingly demand robust performance data and clear value propositions for new diagnostics. As competition intensifies, companies that can demonstrate interoperability, clinical utility, and operational support across diverse care settings will be best placed to capture long-term clinical and commercial relevance.

Practical strategic actions for manufacturers, providers, and payers to accelerate adoption, de-risk operations, and align innovations with payer and clinical priorities

Industry leaders should prioritize a portfolio approach that balances investments in high-impact instruments with scalable consumable solutions that enable broad reach. By emphasizing modular product architectures and flexible service agreements, manufacturers can reduce procurement friction for hospitals and ambulatory surgical centers while enabling diagnostics laboratories to streamline throughput. In parallel, targeted clinical evidence generation focused on patient outcomes, cost-effectiveness, and real-world utility will strengthen negotiations with payers and support guideline inclusion. Establishing early and sustained dialogue with reimbursement authorities and health technology assessment bodies will also expedite pathways to coverage and adoption.

To mitigate trade and supply risks, organizations should diversify supplier bases and consider regional manufacturing or assembly hubs that reduce exposure to tariff volatility. Engaging in strategic partnerships with local distributors and research centers can accelerate market entry and ensure cultural alignment in outreach campaigns. Operationally, investing in digital platforms that facilitate patient reminders, remote specimen tracking, and seamless laboratory reporting will enhance adherence rates and clinician satisfaction. Finally, companies should cultivate clinician champions and collaborative pilot programs that demonstrate workflow integration, patient acceptability, and downstream clinical benefits. Together, these actions will create a resilient, evidence-backed approach to expanding the adoption of effective colorectal cancer screening and diagnostic solutions.

Transparent mixed-methods research approach describing primary engagement, evidence triangulation, and quality assurance processes used to generate the analysis

The analysis synthesizes evidence from a structured mixed-methods approach combining primary qualitative engagement with clinical experts, laboratory directors, and procurement leaders alongside systematic review of peer-reviewed clinical literature and public regulatory documents. Primary research included in-depth interviews to capture operational constraints, procurement behaviors, and clinical preferences across hospitals, ambulatory surgical centers, diagnostics laboratories, and research institutes. Secondary sources were used to contextualize clinical guidelines, technological trajectories, and regulatory environments, ensuring interpretation of trends aligned with contemporary practice.

Data triangulation techniques were applied to reconcile findings from diverse information streams, and iterative validation with domain experts refined thematic conclusions and recommendations. The segmentation framework was mapped against modality characteristics, product types, clinical applications, and end-user workflows to produce actionable insights tailored to decision-making contexts. Limitations were acknowledged where data heterogeneity or regional variance reduced comparability, and sensitivity checks were conducted to ensure that conclusions reflect robust directional trends rather than single-source signals. Quality assurance procedures included expert review cycles and cross-validation of clinical claims against authoritative guideline statements to preserve factual accuracy and relevance for stakeholders.

A concise synthesis of the strategic priorities and evidence-based imperatives that will govern adoption and impact in colorectal cancer screening and diagnostics

The colorectal cancer screening and diagnostics landscape is transitioning toward more patient-centric, evidence-driven, and operationally integrated models of care. Noninvasive modalities and consumable-centric offerings are expanding access and alleviating capacity constraints, while imaging and endoscopic platforms continue to offer definitive diagnostic and therapeutic capabilities. Trade policy and procurement dynamics add another layer of strategic complexity, underscoring the importance of supply chain resilience and localized approaches to manufacturing and distribution.

For stakeholders across the value chain, success will hinge on the ability to demonstrate clinical utility, operational value, and alignment with reimbursement priorities. Companies that build interoperable solutions, invest in rigorous clinical and real-world evidence, and cultivate collaborative partnerships with providers and payers will secure enduring advantage. At the same time, health systems that adopt organized screening programs, leverage digital engagement, and optimize procedural capacity can improve participation rates and downstream outcomes. The coming phase will reward those who couple technical innovation with pragmatic execution, ensuring that advances in diagnostics translate into measurable improvements in population health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colorectal Cancer Screening & Diagnostic Market, by Type

  • 8.1. Screening Tests
    • 8.1.1. Blood Tests
    • 8.1.2. Imaging Tests
      • 8.1.2.1. Colonoscopy
      • 8.1.2.2. CT Colonography
      • 8.1.2.3. Flexible Sigmoidoscopy
  • 8.2. Stool Tests
    • 8.2.1. Fecal Immunochemical Test
    • 8.2.2. Guaiac-Based Fecal Occult Blood Test
    • 8.2.3. Multitarget Stool DNA Testing

9. Colorectal Cancer Screening & Diagnostic Market, by Product

  • 9.1. Consumables
    • 9.1.1. Kits
    • 9.1.2. Reagents
  • 9.2. Instruments
    • 9.2.1. CT Scanners
    • 9.2.2. Endoscopes

10. Colorectal Cancer Screening & Diagnostic Market, by Application

  • 10.1. Disease Monitoring
  • 10.2. Early Detection
  • 10.3. Prognosis Assessment

11. Colorectal Cancer Screening & Diagnostic Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostics Laboratories
  • 11.3. Hospitals
  • 11.4. Research Institutes

12. Colorectal Cancer Screening & Diagnostic Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Colorectal Cancer Screening & Diagnostic Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Colorectal Cancer Screening & Diagnostic Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Colorectal Cancer Screening & Diagnostic Market

16. China Colorectal Cancer Screening & Diagnostic Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Agilent Technologies, Inc.
  • 17.8. Bayer AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. bioMerieux SA
  • 17.12. Bristol-Myers Squibb Company
  • 17.13. Clinical Genomics Technologies Pty Ltd.
  • 17.14. Eiken Chemical Co., Ltd.
  • 17.15. Epigenomics AG
  • 17.16. Exact Sciences Corp.
  • 17.17. F. Hoffmann-La Roche Ltd.
  • 17.18. Fujifilm Holdings Corporation
  • 17.19. GE HealthCare Technologies, Inc.
  • 17.20. Guardant Health, Inc.
  • 17.21. Hologic, Inc.
  • 17.22. Illumina, Inc.
  • 17.23. KARL STORZ SE & Co. KG
  • 17.24. Medtronic PLC
  • 17.25. Merck KGaA
  • 17.26. Myriad Genetics, Inc.
  • 17.27. Novartis AG
  • 17.28. Novigenix SA
  • 17.29. Olympus Corporation
  • 17.30. Prenetics Global Limited
  • 17.31. QIAGEN N.V.
  • 17.32. Quest Diagnostics Incorporated
  • 17.33. Sanofi SA
  • 17.34. Siemens AG
  • 17.35. Sysmex Corporation
  • 17.36. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY BLOOD TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COLONOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT COLONOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FLEXIBLE SIGMOIDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY FECAL IMMUNOCHEMICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GUAIAC-BASED FECAL OCCULT BLOOD TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY MULTITARGET STOOL DNA TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY ENDOSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DISEASE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PROGNOSIS ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 175. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 176. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 179. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. GCC COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 205. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 206. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 209. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. G7 COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 212. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 215. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 216. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 218. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 219. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. NATO COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY SCREENING TESTS, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY IMAGING TESTS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY STOOL TESTS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA COLORECTAL CANCER SCREENING & DIAGNOSTIC MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)